Menu Search
Equities

Upstream Bio Inc

UPB:NSQ

Upstream Bio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)26.15
  • Today's Change0.24 / 0.93%
  • Shares traded31.54k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 16:14 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Upstream Bio Inc grew revenues 96.37% from 1.21m to 2.38m while net income improved from a loss of 23.87m to a smaller loss of 20.54m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, Upstream Bio Inc increased its cash reserves by 51.50%, or 8.78m. Cash Flow from Financing totalled 129.55m or 5,443.28% of revenues. In addition the company used 37.93m for operations while cash used for investing totalled 82.84m.
Cash flow per share--
Price/Cash flow per share--
Book value per share4.30
Tangible book value per share4.30
More ▼

Balance sheet in USDView more

Upstream Bio Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio20.90
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.